ASND is tracked by BiotechSign with a current catalyst score of 52/100 and grade C. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, Ascendis Pharma (ASND) has a BiotechSign Catalyst Score of 52/100, rated C. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
Ascendis Pharma (ASND) is the lead sponsor of 10 active clinical trials listed on ClinicalTrials.gov[4], including 2 Phase 3[1], 6 Phase 2[2], 1 Phase 1[3].
Trial NCT05929807[5] evaluates TransCon CNP in Achondroplasia with a target enrollment of 140 participants. Trial NCT07221851[6] evaluates Lonapegsomatropin [SKYTROFA®] in Turner Syndrome with a target enrollment of 186 participants.
No Form 4 insider filings for ASND were recorded at the SEC in the past 30 days[7].